ADORA2A and Parkinson disease: Several studies have reported that novel anti-PD agents targeting α2-adrenergic receptors, adenosine A2A receptors, glutamate receptors and monoamine oxidase-B could improve clinical efficacy, prevent the occurrence of motor complications as well as alleviate LID [11-15].